Gene-Guided Chemo-Free strategy targets AL amyloidosis

NCT ID NCT07687004

First seen Jul 07, 2026 · Last updated Jul 08, 2026 · Updated 1 time

Summary

This study tests two chemotherapy-free treatments for people newly diagnosed with AL amyloidosis, a rare blood disorder. The choice of treatment depends on whether the patient has a specific genetic change called t(11;14). Those with t(11;14) receive a daily pill called sonrotoclax plus dexamethasone, while those without receive injections of an immunotherapy called CM336. The goal is to see if these treatments are safe and can control the disease without chemotherapy.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance
sonrotoclax (BGB-11417) and CM336 (BCMA/CD3 bispecific antibody)
What this could lead to
If successful, this could offer a chemotherapy-free treatment option for AL amyloidosis, potentially reducing side effects while controlling the disease.
What could go wrong
This is an early-phase trial (Phase 1b/2) with a small number of participants, so results may not apply broadly. The treatments may cause serious side effects, including immune reactions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for MULTIPLE MYELOMA (MM) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • Institute of Hematology and Blood Diseases Hospital Chinese Academy of Medical Sciences

    Tianjin, 300020, China

    Contact Phone: •••-•••-•••• Email: •••••@•••••

More trials for these conditions

Other studies related to the condition(s) this trial covers.